Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Spjute

Interventional Pain Medicine Waco, TX Medical Doctor

NPI 1265851232 CMS profile 4222130

3500 Hillcrest Dr Ste 1, Rm 3C444, Waco, TX 76708

Open in the dashboard

General payments

$23,215

435 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Spjute of Waco, TX is reported in the CMS Open Payments database as having received $23,215 across 435 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,533 25
2024 General $5,691 76
2023 General $2,620 55
2022 General $3,091 176
2021 General $1,434 79
2020 General $199 13
2019 General $647 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Spjute
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Adam Spjute were reported at $9,533. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Adam Spjute Interventional Pain Medicine median Middle half National median
2019 $647 $684 $216–$2,079 $163
2020 $199 $382 $122–$1,109 $114
2021 $1,434 $552 $167–$1,554 $132
2022 $3,091 $605 $187–$1,924 $149
2023 $2,620 $671 $195–$1,915 $160
2024 $5,691 $684 $206–$1,837 $164
2025 $9,533 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $19,837 334 payments
  2. Relievant Medsystems, Inc. $1,397 11 payments
  3. AbbVie, Inc. $485 42 payments
  4. Nevro Corp. $411 4 payments
  5. Nalu Medical, Inc. $347 5 payments
  6. Boston Scientific Corporation $282 10 payments
  7. Amgen Inc. $97 5 payments
  8. Medtronic, Inc. $81 5 payments
  9. Teva Pharmaceuticals USA, Inc. $52 3 payments
  10. Biodelivery Sciences International, Inc. $49 4 payments
  11. Other $176 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,913 414 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $4,400 2 payments
  3. Travel and Lodging $4,154 15 payments
  4. Consulting Fee $2,748 4 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Structural Heart $8,535 14 payments
  2. OCTRODE $4,018 97 payments
  3. PROCLAIM Neuromodulation $3,314 99 payments
  4. Intracept Pain $1,397 11 payments
  5. Intracept Pain $1,115 9 payments
  6. Intracept Pain $1,115 9 payments
  7. Intracept Pain $1,115 9 payments
  8. Proclaim IPG $858 35 payments
  9. PROCLAIM Structural Heart $593 4 payments
  10. PROCLAIM Neuromodulation $550 5 payments
  11. Other $4,317 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

5,718

Median for Anesthesiology: 322

Drug cost

$185,675

Median for Anesthesiology: $8,738

Branded share of claims

82.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 3,765 $128,281
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 509 $12,747
Xtampza Er Oxycodone Myristate Brand 24 $9,479
Morphine Sulfate Er Morphine Sulfate Brand 341 $7,367
Oxycontin Oxycodone Hcl Brand 14 $4,969
Hydrocodone Bitartrate Er Hydrocodone Bitartrate Brand 13 $4,426
Fentanyl Generic 31 $2,703
Gabapentin Generic 161 $2,388
Oxycodone Hcl Generic 162 $1,890
Tizanidine Hcl Generic 77 $1,827

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$286,120

Of which drugs: $702

Medicare patients

380

Average age 70

Services billed

3,998

234 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Ischemic heart disease 31%
Depression 31%
COPD 26%
Chronic kidney disease 21%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 118 646 $499
Injection, fentanyl citrate, 0.1 mg J3010 Office 97 176 $125
Injection, midazolam hydrochloride, per 1 mg J2250 Office 98 327 $34
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 280 $23
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 56 75 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $29
$29 — —
QULIPTA
  • AbbVie, Inc. $29
$29 — —
NURTEC ODT
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

435 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record